Renal artery stenosis following nilotinib administration in a patient with chronic myelogenous leukemia

DOI Web Site PubMed
  • HATSUSE Mayumi
    Department of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center
  • DAIKOKU Yuka
    Department of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center
  • TAMOTO Yuta
    Department of Nephrology, Kyoto Prefectural University of Medicine
  • UEHARA Masahiro
    Department of Nephrology, Kyoto Prefectural University of Medicine
  • KITANI Takashi
    Department of Nephrology, Kyoto Prefectural University of Medicine
  • TAMAGAKI Keiichi
    Department of Nephrology, Kyoto Prefectural University of Medicine
  • FUCHIDA Shin-ichi
    Department of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center
  • OKANO Akira
    Department of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center
  • MURAKAMI Satoshi
    Department of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center
  • SHIMAZAKI Chihiro
    Department of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center

Bibliographic Information

Other Title
  • Nilotinib投与後に腎動脈狭窄を発症した慢性骨髄性白血病
  • 症例報告 第4回日本血液学会関東甲信越地方会 奨励賞 Nilotinib投与後に腎動脈狭窄を発症した慢性骨髄性白血病
  • ショウレイ ホウコク ダイ4カイ ニホン ケツエキ ガッカイ カントウ コウシンエツチホウカイ ショウレイショウ Nilotinib トウヨ ゴ ニ ジンドウミャク キョウサク オ ハッショウ シタ マンセイ コツズイセイ ハッケツビョウ

Search this article

Abstract

<p>A 63-year-old male was diagnosed as having chronic phase CML in 2001. He obtained a major molecular response with imatinib (IM). In 2012, amulodipin was started for hypertension. In January 2013, IM was switched to nilotinib (NIL) in a clinical trial, and in February 2015, NIL was discontinued because MR4.5 had been maintained for two years. One month later, he was admitted to our hospital because of headache and high blood pressure (194/108 mmHg). His urine test showed protein 3+ and occult blood 2+. His eGFR rapidly deteriorated from 45.6 to 28.5 after admission. MR angiography showed left renal artery stenosis. He thus underwent angioplasty of the left renal artery with a stent implantation. His renal function subsequently improved. Cardiovascular events such as PAOD (peripheral artery occlusive disease) during NIL treatment were recently reported. However, to date, only four cases including our present patient with renal artery stenosis associated with NIL have been reported. These observations suggest assessment of risk factors for cardiovascular events at the start of NIL and careful monitoring to be important during tyrosine kinase inhibitor treatment of CML patients.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 58 (1), 15-19, 2017

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top